Listing in mid 2019, Singapore and Perth-based Osteopore (OST) is a regenerative medicine company devoted to developing and manufacturing polymer implants for surgical procedures.
The company’s products are being used in Australia and Europe to plug burr holes drilled in the skull for brain surgery and for skull and face (craniofacial) surgery. The material is “bioresorbable”, meaning it is resorbed by the body and replaced by the patient’s own bone.
Last quarter Osteopore signed three distribution agreements that cover the Australian, New Zealand, German, Austrian, Swedish, Norwegian, Danish and Finnish markets, and is working with a medical school in Singapore on the possibility of using its implants in reconstructing lower jawbones.
Since listing, OST has not really gone anywhere. Hoovered up capital, including a $8.5M placement last August. The July kick was when it “Signed an initial US distribution agreement” only to follow with a clarification soon afterwards
but is it rocket science?